News Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 Staff September 11, 2023 Post Views: 39 Related Continue Reading Previous Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research ConferenceNext Major shareholder announcement – BlackRock, Inc. More Stories Healthcare Mental Health News Nursing Supporting Indigenous Communities: LifeLabs’ Efforts to Provide Health Equity on National Day of Truth and Reconciliation Staff October 1, 2023 Coronavirus Healthcare News SmileDirectClub Seeks to Execute Comprehensive Recapitalization to Strengthen the Business for Sustainable Growth Staff September 30, 2023 Cancer News Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Staff September 30, 2023
